Acute Leukemias Update — Volume 1, Issue 2


ONUL117

Interview with Wendy Stock, MD

Track 1: Case: A 70-year-old man with relapsed/refractory acute lymphoblastic leukemia (ALL) receives the bispecific T-cell engaging antibody blinatumomab as salvage therapy
Track 2: Investigation of blinatumomab-based regimens as front-line therapy for ALL
Track 3: Dosing and tolerability of asparaginase preparations in ALL
Track 4: Chimeric antigen receptor T-cell (CAR-T) therapy in ALL
Track 5: Cytokine release syndrome and neurotoxicity with CAR-T therapy
Track 6: Durability of response to CAR-T therapy and use of the antibody-drug conjugate inotuzumab ozogamicin after disease progression
Track 7: Activity and tolerability of inotuzumab ozogamicin in ALL
Track 8: Roles of CAR-T therapy, blinatumomab and inotuzumab ozogamicin in clinical practice and integration into ALL treatment algorithms
Track 9: Case: A 78-year-old woman with a previously untreated antecedent myeloproliferative neoplasm experiences transformation to IDH2 mutation-positive acute myeloid leukemia (AML)
Track 10: Beat AML Master Trial: A protocol for biomarker-based treatment
Track 11: Recently FDA-approved IDH2 inhibitor enasidenib for patients with AML
Track 12: Liposomal cytarabine/daunorubicin (CPX-351) for secondary AML
Track 13: Recent FDA approvals of enasidenib, midostaurin, CPX-351 and gemtuzumab ozogamicin in AML
Track 14: Case: A 26-year-old woman with newly diagnosed FLT3 mutation-positive AML receives midostaurin and chemotherapy on the Phase III CALGB-10603 (RATIFY) trial
Track 15: Case: A 76-year-old woman with relapsed/refractory FLT3 mutation-positive AML receives gilteritinib on a clinical trial
Track 16: Investigational FLT3 inhibitors in AML
Track 17: Efficacy of venetoclax alone and in combination with hypomethylating agents in AML
Track 18: Activity and unique side-effect profile of the investigational hedgehog inhibitor glasdegib in AML
Track 19: Case: A 24-year-old woman with acute promyelocytic leukemia (APL) receives all-trans retinoic acid (ATRA) and arsenic trioxide

Interview with Eytan Stein, MD

Track 1: Case: A 65-year-old woman with relapsed/refractory FLT3-ITD-positive AML receives gilteritinib on an expanded access program
Track 2: Activity and tolerability of midostaurin
Track 3: Specificity of gilteritinib for FLT3 mutation-positive AML
Track 4: Incidence of FLT3 and IDH1/2 mutations in AML and rationale for dual inhibition
Track 5: FLT3 inhibitors for relapsed/refractory AML
Track 6: Case: A 76-year-old man with relapsed/refractory IDH2 mutation-positive AML receives enasidenib on a clinical trial and develops differentiation syndrome
Track 7: Biology of IDH1/2 mutations and incidence in hematologic versus solid tumors
Track 8: IDH1/2 inhibitors for AML
Track 9: Testing for crucial targetable mutations in AML
Track 10: Activity of venetoclax with or without hypomethylating agents in AML
Track 11: Low-dose ara-C with or without glasdegib for previously untreated AML
Track 12: Case: A 69-year-old woman with biopsy-proven leukemia cutis is diagnosed with AML and receives CPX-351
Track 13: Tolerability of CPX-351 compared to standard-formulation cytarabine/daunorubicin
Track 14: Case: A 37-year-old man with high-risk Philadelphia chromosome-negative B-cell ALL
Track 15: Pediatric-inspired induction chemotherapy for high-risk Philadelphia chromosome-negative ALL
Track 16: Use of blinatumomab for patients with minimal residual disease after induction chemotherapy
Track 17: CAR-T therapy for high-risk ALL; management of cytokine release syndrome
Track 18: Recent FDA approval of inotuzumab ozogamicin for relapsed/refractory B-cell precursor ALL
Track 19: Similarities and differences between CAR-T therapy and blinatumomab and sequencing these agents in ALL
Track 20: Voluntary market withdrawal of gemtuzumab ozogamicin and recent FDA reapproval
Track 21: Antibody-drug conjugate vadastuximab talirine in AML
Track 22: Case: A 35-year-old man with APL receives ATRA and arsenic trioxide
Track 23: Prompt administration of ATRA and decreasing early deaths in APL
Track 24: Epidemiology of APL; higher incidences among Hispanic women
 
FACULTY
 
Wendy Stock, MD
Anjuli Seth Nayak Professor of
Leukemia Research
Director, Leukemia Program
The University of Chicago Medicine
Chicago, Illinois
 
Eytan Stein, MD
Hematologic Oncologist
Memorial Sloan Kettering
Cancer Center
New York, New York
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida